Operating Income for Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's current operating income (TTM) is $4.27B USD. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingOperating IncomeSwitch metric
TTM (last 4 quarters)
$4.27B
YoY change
-2144.1%
5Y CAGR
+10.8%
Peak year (2025)
$4.76B
Cumulative operating income
$14.90B
Operating Income history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Operating Income history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| Fiscal year | Period ended | Reported | Operating Income | YoY |
|---|---|---|---|---|
| 2025 | $4.76B | -2144.1% | ||
| 2024 | -$232.90M | -106.1% | ||
| 2023 | $3.83B | -11.0% | ||
| 2022 | $4.31B | +54.8% | ||
| 2021 | $2.78B | -2.6% | ||
| 2020 | $2.86B | +138.5% | ||
| 2019 | $1.20B | +88.5% | ||
| 2018 | $635.15M | +415.4% | ||
| 2017 | $123.24M | +1140.4% | ||
| 2016 | $9.94M | -102.1% | ||
| 2015 | -$468.66M | -32.3% | ||
| 2014 | -$692.41M | -23.4% | ||
| 2013 | -$903.45M | -38841.3% | ||
| 2012 | $2.33M | -98.0% | ||
| 2011 | $113.82M | -116.4% | ||
| 2010 | -$696.08M | +13.5% | ||
| 2009 | -$613.41M | +32.6% | ||
| 2008 | -$462.71M | +10.2% | ||
| 2007 | -$419.79M | +83.3% | ||
| 2006 | -$229.04M | +52.8% | ||
| 2005 | -$149.87M | -3.2% | ||
| 2004 | -$154.81M | -41.5% | ||
| 2003 | -$264.53M | +121.2% | ||
| 2002 | -$119.60M | +30.3% | ||
| 2001 | -$91.80M | +137.3% | ||
| 2000 | -$38.68M | -2.3% | ||
| 1999 | -$39.60M | +22.2% | ||
| 1998 | -$32.40M | +68.8% | ||
| 1997 | -$19.20M | -35.6% | ||
| 1996 | -$29.80M | +12.5% | ||
| 1995 | -$26.50M | +28.0% | ||
| 1994 | -$20.70M | -1825.0% | ||
| 1993 | $1.20M | -112.0% | ||
| 1992 | -$10.00M | +78.6% | ||
| 1991 | -$5.60M | +36.6% | ||
| 1990 | -$4.10M | — |
Operating Income values are taken from Vertex Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Vertex Pharmaceuticals (VRTX) reported operating income of $4.76B – plunged 2144.1% year-over-year.
Vertex Pharmaceuticals operating income compound annual growth for the 2020–2025 (5 years) window is +10.8%, with the latest reading among the more recent periods of the dataset.
Across the available history, operating income reached its high of $4.76B in 2025 and its low of -$903.45M in 2013.
Among 8 Healthcare peers, Vertex Pharmaceuticals (VRTX) ranks 9th; the peer median for operating income is $22.84B.
Vertex Pharmaceuticals Operating Income by Year
Vertex Pharmaceuticals Operating Income 2025: $4.76B
Vertex Pharmaceuticals operating income in 2025 was $4.76B, plunged 2144.1% below 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Operating Income 2024: -$232.90M
Vertex Pharmaceuticals operating income in 2024 was -$232.90M, plunged 106.1% below 2023.
Vertex Pharmaceuticals Operating Income 2023: $3.83B
Vertex Pharmaceuticals operating income in 2023 was $3.83B, declined 11.0% below 2022.
Vertex Pharmaceuticals Operating Income 2022: $4.31B
Vertex Pharmaceuticals operating income in 2022 was $4.31B, surged 54.8% from 2021.
Vertex Pharmaceuticals Operating Income 2021: $2.78B
Vertex Pharmaceuticals operating income in 2021 was $2.78B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Operating Income
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest operating income.
| Company | Operating Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $127.66B | Healthcare |
| Eli Lilly and Company (LLY) | $29.70B | Healthcare |
| Merck & Co., Inc. (MRK) | $26.78B | Healthcare |
| Johnson & Johnson (JNJ) | $25.60B | Healthcare |
| AbbVie Inc. (ABBV) | $20.09B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $18.96B | Healthcare |
| AstraZeneca PLC (AZN) | $13.74B | Healthcare |
| Amgen Inc. (AMGN) | $10.68B | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's operating income?
- Latest reported operating income for Vertex Pharmaceuticals (VRTX) is $4.27B (period ending December 31, 2025).
How has Vertex Pharmaceuticals operating income changed year-over-year?
- Vertex Pharmaceuticals (VRTX) operating income changed -2144.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals operating income?
- Vertex Pharmaceuticals (VRTX) operating income compound annual growth rate is +10.8% over the most recent 5 years available.
When did Vertex Pharmaceuticals operating income hit its highest annual value?
- Vertex Pharmaceuticals operating income reached its highest annual value of $4.76B in 2025.
What was Vertex Pharmaceuticals operating income in 2024?
- Vertex Pharmaceuticals (VRTX) operating income in 2024 was -$232.90M.
What was Vertex Pharmaceuticals operating income in 2025?
- Vertex Pharmaceuticals (VRTX) operating income in 2025 was $4.76B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.